Your session is about to expire
← Back to Search
Dasatinib for Preventing Neuropathy in Gastrointestinal Cancer
Study Summary
This trial is studying side effects and best dose of dasatinib to prevent damage to nerves caused by oxaliplatin in patients with gastrointestinal cancers receiving FOLFOX regimen.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 54 Patients • NCT03023046Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Prevention (dasatinib, mFOLFOX, bevacizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Dasatinib obtained governmental sanction for use?
"Due to limited data regarding dasatinib's efficacy and safety, our team at Power gauged its risk level as a 1 on a scale of 1-3."
What is the highest number of participants in this medical experiment?
"Affirmative. As per the details available on clinicaltrials.gov, this research trial is currently recruiting participants with 10 enrollees needed for a single site. The trial was first posted on September 2nd 2020 and has been updated as recently as April 25th 2022."
What specific conditions has Dasatinib proven to be beneficial for?
"Dasatinib is an effective treatment for arthritic joints, rectal carcinoma, and non-small cell lung cancer which has spread locally but not developed squamous cells."
Is there an ongoing enrollment process for participants in this clinical research?
"Clinicaltrials.gov reveals that enlistment for this investigation is ongoing, having been first posted on September 2nd 2020 and last modified on April 25th 2022."
What additional research has been done utilizing Dasatinib?
"Currently, 893 clinical trials involving Dasatinib are underway with 264 of them taking place in Phase 3. Of these trials, there are 41209 sites located around the world; a notable concentration is found specifically in Guangzhou, Guangdong."
Share this study with friends
Copy Link
Messenger